Key clinical point: Patients with moderate-to-severe atopic dermatitis (AD) experienced a significantly greater reduction in itch as early as 4 days after treatment with 200 mg abrocitinib compared with dupilumab and placebo.
Major finding: At day 4 after treatment, a significantly higher proportion of patients achieved a ≥4-point improvement in Peak Pruritus Numerical Rating Scale score in the 200 mg abrocitinib group (18.6%) than in the placebo (6.0%; P < .003) and dupilumab (5.6%; P < .001) groups.
Study details: This post hoc analysis of JADE COMPARE included 837 adult patients with moderate-to-severe AD who were randomly assigned to receive oral abrocitinib (200 or 100 mg), subcutaneous dupilumab (300 mg), or placebo with medicated topical therapy for 16 weeks.
Disclosures: This study was funded by Pfizer Inc. Some authors reported ties with various organizations, including Pfizer. Six authors declared being current or former employees and shareholders of Pfizer.
Source: Ständer S et al. Early itch response with abrocitinib is associated with later efficacy outcomes in patients with moderate-to-severe atopic dermatitis: Subgroup analysis of the randomized phase III JADE COMPARE trial. Am J Clin Dermatol. 2022 (Dec 13). Doi: 10.1007/s40257-022-00738-4